Santa Rosa-based Osseon Therapeutics, a biomedical device company in California, has received second patent notice of allowance (NOA) for its spinal vertebral compression fracture (VCF) technology.
Osseon claims that it has two allowed and twelve additional patent applications pending in the US, and several others throughout the world for spinal therapies and devices.
Osseon has been marketing its FDA and CE mark cleared ‘Osseoplasty’ system in the US and Europe, since February, 2009 and February, 2010, respectively.
Osseon president and CEO John Stalcup said that this second patent allowance for Osseon’s spinal VCF technology is another cornerstone for the company’s intellectual property foundation.
“We continue to strengthen their intellectual property position and strive to obtain additional patents in the future on various aspects of the Osseoflex steerable and curvable needle and the novel methods for bone cement delivery, which enable a safe, effective, and minimally invasive approach for spine disease treatment,” Stalcup said.